SCHEMBL3852292

SCHEMBL3852292

CCOC(=O)c1c(O)c(C(C)C)nn(Cc2ccc(F)cc2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.45
MAPT P10636 3/20 0.45
PKM P14618 1/20 0.45
MAPK1 P28482 1/20 0.42
LMNA P02545 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 5/20 0.40
MEN1 O00255 3/20 0.40
HPGD P15428 3/20 0.40
KMT2A Q03164 3/20 0.40
ALOX12 P18054 1/20 0.40
CCR6 P51684 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 2/20 0.39
HTT P42858 1/20 0.39
FEN1 P39748 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3849098 0.89 MAPK1 (0.38) KDM4EMAPTPKMMAPK1LMNA
SCHEMBL3853119 0.89 MAPK1 (0.55) KDM4EMAPTMAPK1LMNAALDH1A1
SCHEMBL3849121 0.87 MAPK1 (0.48) KDM4EMAPTMAPK1LMNANPC1
SCHEMBL3856858 0.87 ALDH1A1 (0.46) KDM4EMAPK1LMNAALDH1A1MEN1
SCHEMBL3856749 0.86 SMN1; SMN2 (0.43) KDM4EMAPTMAPK1LMNAALDH1A1
SCHEMBL3851808 0.85 ALDH1A1 (0.42) KDM4EMAPTPKMLMNANPC1
SCHEMBL3847603 0.85 DPP4 (0.40) KDM4EMAPTPKMMAPK1LMNA
SCHEMBL3849377 0.83 KDM4E (0.44) KDM4EMAPK1LMNANPC1RAB9A
SCHEMBL3855997 0.82 ALDH1A1 (0.45) KDM4ELMNAALDH1A1MEN1HPGD
SCHEMBL3849080 0.82 PDE4B (0.42) KDM4EMAPTMAPK1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2889289-A1 Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors GlaxoSmithKline LLC (US) 2015-07-01 EP disclosed
US-RE44613-E1 N-substituted glycine derivatives: hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-11-26 US disclosed
CN-101626685-B N-substituted glycine derivatives: hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2013-03-13 CN disclosed
US-7608621-B2 Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production SMITHKLINE BEECHAM, CORP. (US) 2009-10-27 US disclosed
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors EGLN2, EGLN3, HIF1AN KDM4E 527/4885MAPT 4802/4885PKM 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.